Patent ID: 8247537

Claim:
An isolated monoclonal antibody or antigen binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein: (a) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 26; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 46 and conservative modifications thereof; (b) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 27; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 47 and conservative modifications thereof; (c) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 48 and conservative modifications thereof; (d) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 49 and conservative modifications thereof; (e) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 29; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 50 and conservative modifications thereof; (f) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 30; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 51 and conservative modifications thereof; (g) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 31; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 52 and conservative modifications thereof; (h) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 82 and conservative modifications thereof; (i) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 97 and conservative modifications thereof; or (j) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 89; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 92 and conservative modifications thereof; and wherein antibody or antigen-binding portion thereof specifically binds to human BTLA.